Post-Kidney Transplantation Malignancy: Risk, Pathogenesis, and Management

Elmukhtar Habas¹, Amnna Rayani², Aml Habas³, Ala Habas⁴, Abdulrahaman Hamad⁵, Eshrak Habas⁶, Almehdi Errayes¹

Keywords: Post-renal transplant, malignancy after renal transplant, immunosuppression andmalignancy, solid organ transplantation and cancer, mTOR inhibitors, CNI

DOI: 10.63475/yjm.v5i2.0459

DOI URL: https://doi.org/10.63475/yjm.v5i2.0459

Publish Date: 22-07-2026

Download PDF

Pages: 274 - 286

Downloads: 5

Citation: 0

Author Affiliation:

1 Professor and Senior Consultant, Department of Medicine, Hamad General Hospital, Qatar University, Doha, Qatar
2 Professor and Senior Consultant, Department of Pediatrics, University of Tripoli, Tripoli, Libya
3 Specialist Hematology, Children’s University Hospital, Open Libyan University, Tripoli, Libya
4 Resident, Internal Medicine and Nephrology, Tripoli Central Hospital, University of Tripoli, Tripoli, Libya
5 Consultant, Department of Medicine, Hamad General Hospital, Doha, Qatar
6 Resident, Radiology Department, University of Tripoli, Tripoli, Libya
7 Senior Consultant, Department of Medicine, Hamad General Hospital, Doha, Qatar

Abstract

The rising incidence of cancer in kidney transplant patients poses a significant barrier to longterm patient and graft survival. Immunosuppression is a primary component in cancer risk, although the interaction of recipient characteristics, viral oncogenesis, and donor-related factors complicates risk assessment. Current research highlights the increased prevalence and mortality linked to some malignancies, including lymphomas, skin cancers, and virus-associated tumors, as well as the limited effectiveness of some existing preventative and treatment approaches. Despite progress, significant challenges persist, particularly in balancing immunosuppression and cancer control, defining the role of prophylactic vaccinations, and validating customized screening techniques. This review examines the pathophysiological mechanisms, evaluates guidelines, and presents contemporary data on the incidence and management of post-kidney transplantation malignancies, highlighting both recent advances and unresolved issues. The current evidence, largely constrained by observational and registry-based studies, underscores the urgent need for prospective research. There is an urgent requirement for prospective research to enhance personalized care, facilitate early detection, and provide safer immunosuppressive protocols. Collaboration among nephrology, oncology, and infectious disease specialists is crucial to improve care and increase survival in this at-risk group.

---